# OnCo record hr-positive-early-high-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hr-positive-early-high-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hr-positive-early-high-risk" ;
  schema:name "High-risk early HR-positive breast cancer"@en ;
  schema:alternateName "High-risk early hormone receptor-positive, HER2-negative breast cancer"@en, "Node-positive luminal breast cancer"@en, "Stage II to III HR-positive breast cancer"@en ;
  schema:description "Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/hr-positive-early-high-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Breast_cancer> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1804710>, <https://doi.org/10.1200/JCO.20.02514>, <https://doi.org/10.1056/NEJMoa2305488>, <https://en.wikipedia.org/wiki/Breast_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/lidera/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/nct03725059/>, <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/artera-ai-breast/> ;
  onco:standardOfCare <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/mammaprint/>, <https://onco.cc/trials/tailorx/>, <https://onco.cc/trials/rxponder/>, <https://onco.cc/trials/mindact/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/exemestane/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/goserelin/>, <https://onco.cc/trials/soft-text/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/trials/monarche/>, <https://onco.cc/trials/natalee/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/denosumab/> .